{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:08Z","timestamp":1788225308779,"version":"build-2803163510"},"reference-count":74,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalization in infants and the elderly. Newly approved vaccines and the prophylactic antibody nirsevimab have heightened interest in RSV immunologic surveillance, necessitating the development of high-throughput assays assessing anti-RSV neutralizing activity. Quantitative viral neutralization remains the best correlate of protection for RSV infection and the gold standard for RSV immunological testing. Here, we developed a high-throughput RSV strain A2 focus-reduction neutralization test validated to CLIA\/GCLP standards using both clinical specimens and commercially available reference sera. The assay is highly accurate, generating reference serum neutralizing titers within twofold of established assays, with an analytical measurement range between 8 and 1,798 international units (IU) per mL. Neutralizing activity measured by the assay strongly correlated with antibody titer determined via indirect ELISA (\n                      <jats:italic toggle=\"yes\">\u03c1<\/jats:italic>\n                      = 1.0,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0014). Individuals recently having tested RT-qPCR positive for RSV had a 7.5-fold higher geometric mean neutralizing titer relative to RSV PCR negatives (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). The validated assay was then used to investigate the immunity debt hypothesis for resurgent RSV outbreaks in the 2022\u20132023 season, using adult clinical remnant sera sent for HSV-1\/2 antibody testing. There was no difference in geometric mean anti-RSV neutralizing titers between sera sampled before and after the 2022\u20132023 RSV outbreak (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.68). These data are consistent with limited changes in RSV neutralizing antibody levels in adults across the 2022\u20132023 RSV outbreak.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>IMPORTANCE<\/jats:title>\n                    <jats:p>Population surveillance studies of serum neutralizing activity against RSV are crucial for evaluating RSV vaccine efficacy and vulnerabilities to new strains. Here, we designed and validated a high-throughput assay for assessing anti-RSV neutralizing activity, standardized its measurements for comparison with other methodologies, and demonstrated its applicability to real-world samples. Our assay is precise, linear, and yields measurements consistent with other standardized assays, offering a methodology useful for large-scale studies of RSV immunity. We also find no significant difference in neutralizing titers among adults between taken before and after large RSV outbreaks associated with the latter stages of the COVID-19 public health emergency, underlining the need for a greater understanding of the dynamics of serological responses to RSV infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.01739-25","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:11:22Z","timestamp":1766513482000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Corrected and republished from: \u201cClinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021\u20132023 RSV outbreaks to investigate the immunity debt hypothesis\u201d"],"prefix":"10.1128","volume":"14","author":[{"given":"Eli A.","family":"Piliper","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Reed","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-0527","authenticated-orcid":true,"given":"Alexander L.","family":"Greninger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center","place":["Seattle, USA"]},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","unstructured":"Respiratory Syncytial Virus (RSV). 2022. Respiratory Syncytial Virus (RSV) | NIH: National Institute of Allergy and Infectious Diseases. Available from: https:\/\/www.niaid.nih.gov\/diseases-conditions\/respiratory-syncytial-virus-rsv"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.11.106"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.12.010"},{"key":"e_1_3_4_5_2","unstructured":"Commissioner O. 2023. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. FDA. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15020280"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00544-8"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/idr14040059"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S396434"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14647"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00749-3"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00085-21"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01113-x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae140"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115353"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2021.10.001"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac192"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15040939"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02316-5"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2017.0147"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(81)80829-3"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-64-9-1867"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(06)80027-2"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.043"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.07.053"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2009.09.006"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.046"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12201"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2018.10.022"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.053"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00225-17"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S438915"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav9033"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.095"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.10.087"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa0698"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.9.6.1235-1239.2002"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113160"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250516"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06179-11"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00003-08"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03789-22"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2022.114590"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113054"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.06.017"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11071789"},{"key":"e_1_3_4_48_2","unstructured":"Santana-Rodr\u00edguez E M\u00e9ndez-Orta MK Sardina-Gonz\u00e1lez T Pilar M Brizuela SC Sordo-Puga Y P\u00e9rez-P\u00e9rez D Oliva-C\u00e1rdenas A Vargas-Hern\u00e1ndez M Duarte CA Fr\u00edas-Lepoureaux MT Su\u00e1rez-Pedroso M. 2022. Consistency of the neutralizing peroxidase linked assay for classical swine fever and homologation with an OIE reference laboratory"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262922"},{"key":"e_1_3_4_50_2","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster DA","year":"2008","unstructured":"Armbruster DA, Pry T. 2008. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev Aust Assoc Clin Biochem 29 Suppl 1:S49\u201352.","journal-title":"Clin Biochem Rev Aust Assoc Clin Biochem"},{"key":"e_1_3_4_51_2","unstructured":"CDC. 2024. RSV State Trends - NREVSS | CDC. Available from: https:\/\/www.cdc.gov\/surveillance\/nrevss\/rsv\/state.html"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207566"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2022.123409"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3687-8_7"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213836"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.03.017"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.15108.1"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175792"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081717"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-38919-1_3"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad076"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2284"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.06.016"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab612"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00763-0"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","unstructured":"Walker G Foster C Sevendal A Domazetovska A Kamalakkannan A Williams PCM Kim KW Condylios A Stelzer-Braid S Bartlett A Rawlinson W. 2023. Genomic and Immunological characterisation shows increased respiratory syncytial virus cases not due to waning antibody mediated immunity. SSRN. Rochester NY. doi:10.2139\/ssrn.4515871","DOI":"10.2139\/ssrn.4515871"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102089"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26370"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060624"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28830"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2904.221834"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2216153"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(96)00096-5"},{"key":"e_1_3_4_74_2","unstructured":"Landis JT Peng A An H Bailey AG Dittmer DP Marron JS. 2021. dr4pl: Dose Response Data Analysis using the 4 Parameter Logistic (4pl) Model (2.0.0)"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj0902029"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01739-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01739-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:46:09Z","timestamp":1788223569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01739-25"}},"subtitle":[],"editor":[{"given":"Meghan","family":"Starolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,3]]}},"alternative-id":["10.1128\/spectrum.01739-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01739-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2025-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01739-25"}}